Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles

Toxicology

Volumn 144, Issue 1-3, 2000, Pages 197-203

  Lewis, David F V ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Cytochromes P450; Drug metabolism; Lipophilicity; QSARs

Indexed keywords

ALCOHOL; AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; BENZENE; CHLORPHENOTANE; CHLORPROMAZINE; CITALOPRAM; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DAPSONE; DEXAMETHASONE; DIAZEPAM; DICLOFENAC; DIMETHYLNITROSAMINE DEMETHYLASE; HALOTHANE; IFOSFAMIDE; IMIDAZOLE; INDUSTRIAL CHEMICAL; METOPROLOL; NAPROXEN; PESTICIDE; PROPRANOLOL; QUINIDINE; RIFAMPICIN; TIENILIC ACID; UNINDEXED DRUG; UNSPECIFIC MONOOXYGENASE;

DRUG METABOLISM; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HYDROGEN BOND; LIPOPHILICITY; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; XENOBIOTIC METABOLISM;

EID: 0034600005     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(99)00207-3     Document Type: Article

References (37)

1. Cnubben N.H.P., Peelen S., Borst J.-W., Vervoort J., Veeger C., Rietjens I.M.C.M. Molecular orbital-based quantitative structure-activity relationships for the cytochrome P450-catalyzed 4-hydroxylation of halogenated anilines. Chem. Res. Toxicol. 7:1994;590-598.
2. Dollery C. Therapeutic Drugs. second ed. 1999;Chruchill-Livingstone, Edinburgh.
3. Hansch C., Björkroth J.P., Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 76:1987;663-687.
4. Hansch C., Leo A. Substituent Constants for Correlation Analysis in Chemistry and Biology. 1978;Wiley, New York.
5. Lewis D.F.V. Cytochromes P450: Structure, Function and Mechanism. 1996;Taylor and Francis, London.
6. Lewis D.F.V., Eddershaw P.J., Goldfarb P.S., Tarbit M.H. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica. 26:1996;1067-1086.
7. Lewis D.F.V. Quantitative structure-activity relationships in substrates, inducers and inhibitors of cytochrome P4501 (CYP1). Drug. Metab. Rev. 29:1997;589-650.
8. Lewis D.F.V., Eddershaw P.J., Goldfarb P.S., Tarbit M.H. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP192: structural studies on specific CYP2D6 substrate metabolism. Xeniobiotica. 27:1997;319-340.
9. Lewis D.F.V. Models to predict drug metabolism. Manuf. Chem. 69:1998;15-19.
10. Lewis D.F.V. Molecular modelling in drug metabolism: the cytochromes P450. Gooderham N.J. Drug Metabolism Towards the Next Millenium. 1998;1-12 IOS Press, Amsterdam.
11. Lewis D.F.V. The CYP2 family: models, mutants and interactions. Xenobiotica. 28:1998;617-661.
12. Lewis D.F.V., Lake B.G. Molecular modelling of omeprazole interactions with cytochrome P450 isozymes is consistent with metabolism in human liver microsomes. Toxicology. 125:1998;31-44.
13. Lewis D.F.V., Lake B.G. Molecular modelling of the rat peroxisome proliferator-activated receptor α (rPPARα) by homology with the human retinoic acid X receptor α (hRXRα) and investigation of peroxisome proliferator binding interactions: QSARs. Toxicol. Vitrol. 12:1998;619-632.
14. Lewis D.F.V., Pratt J.M. The P450 catalytic cycle and oxygenation mechanism. Drug Metab. Rev. 30:1998;739-786.
15. Lewis D.F.V., Dickins M., Eddershaw P.J., Goldfarb P.S., Tarbit M.H. Molecular modelling of human CYP2C subsfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica. 28:1998;235-268.
16. Lewis D.F.V., Ioannides C., Parke D.V. An improved version of the COMPACT procedure for the evaluation of P450-mediated chemical activation. Drug. Metab. Rev. 30:1998;709-737.
17. Lewis D.F.V., Ioannides C., Parke D.V. Cytochrome P450 and species differences in xenobiotic metabolism and activation of carcinogens. Environ. Health Perspect. 106:1998;633-641.
18. Lewis D.F.V., Eddershaw P.J., Dickins M., Tarbit M.H., Goldfarb P.S. Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chem. Biol. Interact. 115:1998;175-199.
19. Lewis D.F.V. Frontier orbitals in chemical and biological activity: quantitative relationships and mechanistic implications. Drug. Metab. Rev. 31:1999;755-816.
20. Lewis D.F.V. Molecular modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate specificity" Exp. Toxicol. Pathol. 51:1999;369-374.
21. Lewis, D.F.V., 1999c. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human P450 substrate specificity, Biochemical Pharmacology, in press.
22. Lewis D.F.V., Lake B.G. Molecular modelling of CYP4A subfamily members. Xenobiotica. 29:1999;763-781.
23. Lewis D.F.V., Dickins M., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Cytochrome P450 substrate specificities, subsrtate structural templates and enzyme active site geometries. Drug Metab. Drug Interact. 15:1999;1-49.
24. Lewis D.F.V., Dickins M., Lake B.G., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology. 133:1999;1-33.
25. Lewis, D.F.V., Lake, B.G., Bird, M.G., Dickins, M., Eddershaw, P.J., Tarbit, M.H., Goldfarb, P.S., 1999c. Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the CYP2E1 isoform. Xenobiotica 29 in press.
26. Lewis D.F.V., Lake B.G., Dickins M., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Molecular modelling of the phenobarbital-inducible P450 isoforms: CY2B1, CYP2B4 and CYP2B6 by homology with the substrate-bound CYP102 crystal structure, and evaluation of CYP2B substrate binding affinity. Xenobiotica. 29:1999;361-393.
27. Lewis, D.F.V., Lake, B.G., George, S., Dickins, M., Beresford, A.P., Eddershaw, P.J., Tarbit, M.H., Goldfarb, P.S., Guengerich, F.P., 1999e. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102, Toxicology 133 in press.
28. Rendic S., Di Carlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab. Rev. 29:1997;413-580.
29. Roffey, S.J., 1993. Structure-activity relationships in the metabolism of tertiary amines by cytochromes P450, Ph.D. Thesis, University of Surrey, Guildford, Surrey, UK.
30. 3 radical reactivity in the troposhere. Atmos. Environ. 24A:1990;73-78.
31. Sangster J. Octanol-water coefficients of simple organic compounds. J. Phys. Chem. Ref. Data. 18:1989;1111-1229.
32. Smith D.A., Ackland M.J., Jones B.C. Properties of cytochrome P450 isozymes and their substrates. I. Active site characteristics. Drug Discov. Today. 2:1997;406-414.
33. Smith D.A., Ackland M.J., Jones B.C. Properties of cytochrome P450 isozymes and their substrates. Part II. Properties of cytochrome P450 substrates. Drug Discov. Today. 2:1997;479-486.
34. Suzuki T., Kudo Y. Automatic log P estimation based on combined additive modeling methods. J. Comput. Aided Mol. Design. 4:1990;155-198.
35. Traylor T.G., Xu F. Model reactions related to cytochrome P450: effects of alkene structure on the rates of epoxide formation. J. Am. Chem. Soc. 110:1988;1953-1958.
36. Tyrakowska B., Cnubben N.H.P., Soffers A.E.M.F., Wobbes T., Rietjens I.M.C.M. Comparative MO-QSAR studies in various species including man. Chem. Biol. Interact. 100:1996;187-201.
37. Yin H., Anders M.W., Korzekwa K.R., Higgins L., Thummel K.E., Kharasch E.D., Jones J.P. Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc. Natl. Acad. Sci. USA. 92:1995;11076-11080.